Nisa Investment Advisors LLC Sells 7,025 Shares of Abbott Laboratories $ABT

Nisa Investment Advisors LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 511,416 shares of the healthcare product maker’s stock after selling 7,025 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Abbott Laboratories were worth $69,558,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Resonant Capital Advisors LLC raised its position in shares of Abbott Laboratories by 6.1% during the second quarter. Resonant Capital Advisors LLC now owns 14,503 shares of the healthcare product maker’s stock valued at $1,973,000 after buying an additional 834 shares during the last quarter. Wealthfront Advisers LLC raised its stake in shares of Abbott Laboratories by 11.9% in the second quarter. Wealthfront Advisers LLC now owns 181,000 shares of the healthcare product maker’s stock valued at $24,618,000 after purchasing an additional 19,231 shares in the last quarter. Prudent Man Advisors LLC boosted its stake in Abbott Laboratories by 16.1% during the second quarter. Prudent Man Advisors LLC now owns 16,894 shares of the healthcare product maker’s stock worth $2,298,000 after buying an additional 2,349 shares in the last quarter. Topsail Wealth Management LLC lifted its holdings in shares of Abbott Laboratories by 3.1% during the 2nd quarter. Topsail Wealth Management LLC now owns 3,616 shares of the healthcare product maker’s stock worth $492,000 after acquiring an additional 110 shares during the period. Finally, Orion Capital Management LLC increased its stake in Abbott Laboratories by 14.2% in the second quarter. Orion Capital Management LLC now owns 1,772 shares of the healthcare product maker’s stock valued at $241,000 after acquiring an additional 220 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Up 0.3%

ABT opened at $126.78 on Friday. The firm’s fifty day simple moving average is $132.09 and its 200 day simple moving average is $131.61. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The stock has a market capitalization of $220.65 billion, a P/E ratio of 15.89, a P/E/G ratio of 2.41 and a beta of 0.69. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. The firm had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The company’s revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.9%. Abbott Laboratories’s payout ratio is currently 29.57%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.46% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on ABT shares. Wells Fargo & Company increased their target price on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a report on Thursday, October 16th. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $147.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 16th. Raymond James Financial lifted their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Finally, Benchmark started coverage on Abbott Laboratories in a report on Friday, October 10th. They issued a “buy” rating and a $145.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.